RobAiotics builds AI-driven diagnostic and therapeutic tools for neurological conditions, focusing on early autism detection and Alzheimer’s disease progression assessment. Their multilingual machine‑learning models generate objective risk scores and treatment recommendations, delivering production‑ready clinical applications for clinicians and healthcare organizations.
Funding
Funding not disclosed
Founders
Product
Problem
Early detection and accurate diagnosis of neurological conditions such as autism spectrum disorder (ASD) and Alzheimer’s disease are hindered by limited access to specialized assessments, subjective evaluation methods, and delayed intervention, which reduce treatment effectiveness.
Solution
RobAiotics develops AI-driven diagnostic and therapeutic tools that analyze behavioral patterns and cognitive data to identify early signs of ASD and assess Alzheimer’s disease progression. Their machine‑learning models are trained on large medical datasets and incorporate multilingual capabilities to serve diverse populations. The platform delivers production‑ready clinical AI applications that provide healthcare professionals with objective risk scores, progression forecasts, and decision support for treatment planning. By offering MVP demos and ongoing validation, RobAiotics aims to integrate these tools into clinical workflows, enabling faster, data‑driven interventions.
Target Audience
Primary customers are clinicians, neurologists, and healthcare organizations seeking AI‑assisted diagnostic and treatment tools for autism spectrum disorders and Alzheimer’s disease.
Features
- AI models that detect early autism indicators from behavioral pattern analysis across multiple languages
- Machine‑learning algorithms for cognitive assessment and progression modeling in Alzheimer’s disease
- Production‑ready clinical AI applications with diagnostic risk scoring and therapeutic recommendation support
- Multilingual interface to accommodate diverse patient populations and clinicians
- MVP and demo versions available for early testing, with ongoing validation and performance monitoring